EP
KNSA icon

Eversept Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Eversept Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-81,700
Closed -$2.08M – 60
2020
Q2 		$2.08M Buy
+81,700
New +$1.71M 0.29% 48

Other funds holding KNSA

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Eversept Partners's KNSA Position: Q3 2020 in Review

Eversept Partners sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2020, closing a stake of 81,700 shares — an estimated $2.08M sold.

Eversept Partners first reported a position in KNSA in Q2 2020 and held it in 1 quarter. The position peaked at $2.08M in Q2 2020. 104 funds tracked by Wall St. Rank hold KNSA as of Q3 2020.

  • Eversept Partners reported no remaining Kiniksa Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Eversept Partners sold 81,700 Kiniksa Pharmaceuticals shares in Q3 2020, an estimated $2.08M.
  • Eversept Partners first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Eversept Partners's Kiniksa Pharmaceuticals position peaked at $2.08M in Q2 2020.
  • 104 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2020.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.